de la Mare Jo-Anne, Jurgens Tamarin, Edkins Adrienne L
The Biomedical Biotechnology Research Unit, Department of Biochemistry and Microbiology, Rhodes University, Grahamstown, 6139, South Africa.
BMC Cancer. 2017 Mar 16;17(1):202. doi: 10.1186/s12885-017-3190-z.
Tumour metastasis remains the major cause of death in cancer patients and, to date, the mechanism and signalling pathways governing this process are not completely understood. The TGF-β pathway is the most commonly mutated pathway in cancer, however its role in cancer progression is controversial as it can function as both a promoter and a suppressor of metastasis. Although previous studies have suggested a role for the molecular chaperone Hsp90 in regulating the TGF-β pathway, the level at which this occurs as well as the consequences in terms of colon cancer metastasis are unknown.
The paired SW480 and SW620 colon cancer cell lines, derived from a primary tumour and its lymph node metastasis, respectively, were used as an in vitro model to study key cellular processes required for metastasis. The status of the TGF-β pathway was examined in these cells using ELISA, flow cytometry, western blot analysis and confocal microscopy. Furthermore, the effect of addition or inhibition of the TGF-β pathway and Hsp90 on adhesion, migration and anchorage-independent growth, was determined in the cell lines.
When comparing the canonical TGF-β1 pathway in the genetically paired cell lines our data suggests that this pathway may be constitutively active in the SW620 metastasis-derived cell line and not the SW480 primary tumour-derived line. In addition, we report that, when present in combination, TGF-β1 and Hsp90β stimulate anchorage-independent growth, reduce adhesion and stimulate migration. This effect is potentiated by inhibition of the TGF-β1 receptor and occurs via an alternate TGF-β1 pathway, mediated by αvβ6 integrin. Interestingly, in the SW620 cells, activation of this alternate TGF-β1 signalling machinery does not appear to require inhibition of the canonical TGF-β1 receptor, which would allow them to respond more effectively to the pro-metastasis stimulus of a combination of Hsp90β and TGF-β1 and this could account for the increased migratory capacity of these cells.
In this study we report an apparent synergy between TGF-β1 and Hsp90β in stimulating migratory behaviour of colon cancer cells when signalling occurs via αvβ6 integrin as opposed to the canonical TGF-β1 pathway.
肿瘤转移仍然是癌症患者死亡的主要原因,迄今为止,调控这一过程的机制和信号通路尚未完全明确。转化生长因子-β(TGF-β)通路是癌症中最常发生突变的通路,然而其在癌症进展中的作用存在争议,因为它既可以作为转移的促进因子,也可以作为抑制因子。尽管先前的研究表明分子伴侣热休克蛋白90(Hsp90)在调节TGF-β通路中发挥作用,但具体作用水平以及对结肠癌转移的影响尚不清楚。
分别来源于原发性肿瘤及其淋巴结转移灶的配对SW480和SW620结肠癌细胞系,被用作体外模型来研究转移所需的关键细胞过程。使用酶联免疫吸附测定(ELISA)、流式细胞术、蛋白质免疫印迹分析和共聚焦显微镜检查这些细胞中TGF-β通路的状态。此外,在细胞系中确定添加或抑制TGF-β通路和Hsp90对黏附、迁移和非锚定依赖性生长的影响。
在比较基因配对的细胞系中的经典TGF-β1通路时,我们的数据表明该通路可能在源自SW620转移灶的细胞系中组成性激活,而在源自SW480原发性肿瘤的细胞系中并非如此。此外,我们报告,当联合存在时,TGF-β1和Hsp90β会刺激非锚定依赖性生长、降低黏附并促进迁移。这种效应通过抑制TGF-β1受体而增强,并且通过由αvβ6整合素介导的替代TGF-β1通路发生。有趣的是,在SW620细胞中,激活这种替代TGF-β1信号传导机制似乎不需要抑制经典TGF-β1受体,这将使它们能够更有效地响应Hsp90β和TGF-β1组合的促转移刺激,这可以解释这些细胞迁移能力的增加。
在本研究中,我们报告当信号通过αvβ6整合素而非经典TGF-β1通路发生时,TGF-β1和Hsp90β在刺激结肠癌细胞迁移行为方面存在明显的协同作用。